军事知识服务平台
中国恶性肿瘤整合诊治指南:前列腺癌(2026年版)
Chinese Anti-Cancer Association guidelines for holistic integrative management of cancer:prostate cancer(2026 edition)
摘要 前列腺癌是全球男性常见恶性肿瘤之一.近年来,中国前列腺癌发病人数持续增加,初诊晚期患者比例仍相对较高,疾病负担日益加重.随着前列腺特异性抗原筛查、多参数磁共振成像、前列腺特异性膜抗原分子影像、分子病理学和基因检测等诊断技术的发展,以及手术、放疗、新型内分泌治疗、化疗、分子靶向治疗和放射性配体治疗等治疗手段的不断更新,前列腺癌的诊疗模式已逐步转向风险分层、精准治疗和全病程管理.为进一步规范中国前列腺癌的临床诊疗,中国抗癌协会男性生殖系统肿瘤专业委员会组织泌尿外科、肿瘤内科、放疗科、影像科、病理科、核医学科、中医科及康复医学等相关领域专家,在既往指南基础上开展定期更新.本指南已在国际实践指南注册与透明化平台完成注册.制定团队检索并评价国内外相关研究证据,参考国内外权威指南和专家共识,结合中国前列腺癌疾病特征、临床实践及医疗资源现状,经多学科专家讨论形成推荐意见.指南内容涵盖前列腺癌的流行病学与风险分层筛查、诊断与分期、病理学评价和分子检测、局限性前列腺癌治疗、根治性治疗后复发的诊疗、晚期前列腺癌系统治疗、骨相关事件管理、中西医结合治疗、康复及随访.2026年版重点更新了基于个体风险的早期检测策略、多参数磁共振成像和前列腺特异性抗原密度指导下的穿刺决策、分子分型与基因检测、局限性高危前列腺癌围手术期治疗、根治性治疗后复发的危险分层与挽救性治疗、转移性激素敏感性前列腺癌强化治疗、转移性去势抵抗性前列腺癌精准治疗及治疗序贯、前列腺特异性膜抗原靶向放射性配体治疗,以及中西医结合和全程康复管理等内容.本指南旨在为中国各级医疗机构及相关专业人员提供兼顾循证医学证据、临床可及性与患者个体特征的诊疗依据,促进前列腺癌的规范化、精准化和整合化管理.
Abstract:
Prostate cancer is one of the most common malignancies among men worldwide.In China,the number of newly diagnosed cases continues to increase,while a relatively high proportion of patients still present with advanced disease,resulting in a growing disease burden.With advances in prostate-specific antigen-based early detection,multiparametric magnetic resonance imaging,prostate-specific membrane antigen-targeted molecular imaging,molecular pathology,and genomic testing,as well as the continuing development of surgery,radiotherapy,next-generation hormonal therapy,chemotherapy,molecularly targeted therapy,and radioligand therapy,the management of prostate cancer has progressively shifted toward risk stratification,precision treatment,and whole-course disease management.To further standardize the clinical management of prostate cancer in China,the Male Genitourinary Cancer Committee of the Chinese Anti-Cancer Association convened a multidisciplinary panel comprising experts in urologic surgery,medical oncology,radiation oncology,radiology,pathology,nuclear medicine,traditional Chinese medicine,and rehabilitation medicine to periodically update the previous version of the guideline.The guideline was registered on the Practice Guideline Registration for Transparency platform.The development group searched for and appraised relevant evidence from China and other countries,reviewed authoritative clinical practice guidelines and expert consensuses,and formulated recommendations through multidisciplinary discussions,taking into account the disease characteristics,clinical practice,and availability of healthcare resources in China.The guideline covers epidemiology and risk-adapted early detection,diagnosis and staging,pathological assessment and molecular testing,treatment of localized prostate cancer,management of recurrence after radical therapy,systemic treatment of advanced disease,management of skeletal-related events,integrative Chinese and Western medicine,rehabilitation,and follow-up.Major updates in the 2026 edition include risk-adapted early detection;biopsy decision-making guided by multiparametric magnetic resonance imaging and prostate-specific antigen density;molecular classification and genomic testing;perioperative treatment for high-risk localized disease;risk stratification and salvage treatment after radical therapy;treatment intensification for metastatic hormone-sensitive prostate cancer;precision treatment and therapeutic sequencing for metastatic castration-resistant prostate cancer;prostate-specific membrane antigen-targeted radioligand therapy;and integrative Chinese and Western medicine and whole-course rehabilitation.This guideline is intended to provide healthcare professionals at different levels of medical institutions in China with evidence-based and clinically applicable recommendations that incorporate individual patient characteristics,thereby promoting standardized,precise,and integrative management of prostate cancer.